Summary • Vor Biopharma Inc. (VOR) shares increased by 10.9% to $15.01 following new board appointments.• The company announced a $150 million PIPE financing, enhancing growth and strategic leadership ...

Christmas should be a time for reflection. But when families get together, the potential for conflict often increases. We have tips on how to prevent ...

Vor Biopharma ( ($VOR) ) has provided an update. On December 15, 2025, Vor Bio entered into a securities purchase agreement for a $150 million ...

Pep Guardiola's side are into the Carabao Cup semi-finals! Three additional minutes will be played at the end of the second half. The second half between Newcastle and Fulham is underway at St James' ...

Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...

Kick-off at the Etihad between Manchester City and Brentford is fast approaching. Welcome to tonight's coverage of the ...

On Wednesday, Vor Biopharma VOR hit a noteworthy technical benchmark, seeing its Relative Strength (RS) Rating jump into the ...

There's a fledgling aviator out there who will likely be getting an aviation video game this holiday season. Your mother ...

Summary • Vor Biopharma Inc. (VOR) shares rose 5% in pre-market trading to $13.20 following a private placement announcement.

Vor Bio intends to use the net proceeds from the private placement to advance the clinical development of telitacicept, including the ongoing global Phase 3 clinical trial for myasthenia gravis and ...

In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...